{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:55:42Z","timestamp":1793087742717,"version":"4.5.0"},"reference-count":29,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.3201\/eid2707.203900","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T16:42:12Z","timestamp":1624293732000},"page":"1850-1857","source":"Crossref","is-referenced-by-count":37,"title":["Triclabendazole Treatment Failure for<i>Fasciola hepatica<\/i>Infection among Preschool and School-Age Children, Cusco, Peru1"],"prefix":"10.3201","volume":"27","author":[{"given":"Maria L.","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda B.","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"A. Clinton","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Bascope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel M.","family":"Cabada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2707.203900-202106161102-R1","unstructured":"World Health Organization. Fascioliasis diagnosis, treatment and control strategy (updated 2014) [cited 2020 May 28]. https:\/\/www.who.int\/foodborne_trematode_infections\/fascioliasis\/fascioliasis_diagnosis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/0035-9203(88)90222-2","article-title":"Human fascioliasis treated with triclabendazole (Fasinex) for the first time.","volume":"82","author":"Wessely","year":"1988","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.3201\/eid2707.203900-202106161102-R3","doi-asserted-by":"publisher","first-page":"e1720","DOI":"10.1371\/journal.pntd.0001720","article-title":"Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.","volume":"6","author":"Villegas","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.26719\/1999.5.5.888","article-title":"Triclabendazole in the treatment of human fascioliasis: a community-based study.","volume":"5","author":"el-Morshedy","year":"1999","journal-title":"East Mediterr Health J"},{"key":"key-10.3201\/eid2707.203900-202106161102-R5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1590\/0037-8682-0148-2015","article-title":"Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children.","volume":"48","author":"Maco","year":"2015","journal-title":"Rev Soc Bras Med Trop"},{"key":"key-10.3201\/eid2707.203900-202106161102-R6","unstructured":"Centers for Disease Control and Prevention.Fasciola. Resources for health professionals and treatment (updated 2019) [cited 2020 May 28]. https:\/\/www.cdc.gov\/parasites\/fasciola\/health_professionals\/index.html"},{"key":"key-10.3201\/eid2707.203900-202106161102-R7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1440-1681.2004.04093.x","article-title":"Randomized trial of a single, double and triple dose of 10 mg\/kg of a human formulation of triclabendazole in patients with fascioliasis.","volume":"31","author":"Talaie","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key-10.3201\/eid2707.203900-202106161102-R8","unstructured":"US Food and Drug Administration. Drug approval package: Egaten (triclabendazole) 2019 [cited 2020 May 28]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208711Orig1s000TOC.cfm"},{"key":"key-10.3201\/eid2707.203900-202106161102-R9","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.4269\/ajtmh.19-0060","article-title":"Mass drug administration of triclabendazole for Fasciola hepatica in Bolivia.","volume":"100","author":"Mollinedo","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.3201\/eid2707.203900-202106161102-R10","first-page":"67","article-title":"The clinical characteristics of fascioliasis in pediatric patients.","volume":"55","author":"Bayhan","year":"2020","journal-title":"Turk Pediatri Ars"},{"key":"key-10.3201\/eid2707.203900-202106161102-R11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1751-0813.1995.tb03546.x","article-title":"Resistance of Fasciola hepatica to triclabendazole.","volume":"72","author":"Overend","year":"1995","journal-title":"Aust Vet J"},{"key":"key-10.3201\/eid2707.203900-202106161102-R12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.pt.2016.03.002","article-title":"Current threat of triclabendazole resistance in Fasciola hepatica.","volume":"32","author":"Kelley","year":"2016","journal-title":"Trends Parasitol"},{"key":"key-10.3201\/eid2707.203900-202106161102-R13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3201\/eid1806.120302","article-title":"Apparent triclabendazole-resistant human Fasciola hepatica infection, the Netherlands.","volume":"18","author":"Winkelhagen","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R14","doi-asserted-by":"publisher","first-page":"e0004361","DOI":"10.1371\/journal.pntd.0004361","article-title":"Treatment failure after multiple courses of triclabendazole among patients with fascioliasis in Cusco, Peru: a case series.","volume":"10","author":"Cabada","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R15","doi-asserted-by":"publisher","first-page":"e232299","DOI":"10.1136\/bcr-2019-232299","article-title":"Treatment failure after multiple courses of triclabendazole in a Portuguese patient with fascioliasis.","volume":"13","author":"Branco","year":"2020","journal-title":"BMJ Case Rep"},{"key":"key-10.3201\/eid2707.203900-202106161102-R16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.4269\/ajtmh.18-0372","article-title":"Socioeconomic factors associated with Fasciola hepatica infection among children from 26 communities of the Cusco region of Peru.","volume":"99","author":"Cabada","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.3201\/eid2707.203900-202106161102-R17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/20477724.2016.1187361","article-title":"Kato-Katz and Lumbreras rapid sedimentation test to evaluate helminth prevalence in the setting of a school-based deworming program.","volume":"110","author":"Lopez","year":"2016","journal-title":"Pathog Glob Health"},{"key":"key-10.3201\/eid2707.203900-202106161102-R18","unstructured":"Schreiner M. A simple poverty scorecard for Peru 2009 [cited 2021 Jan 14]. https:\/\/www.simplepovertyscorecard.com\/PER_2007_ENG.pdf"},{"key":"key-10.3201\/eid2707.203900-202106161102-R19","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1517\/13543784.14.12.1513","article-title":"Triclabendazole for the treatment of fascioliasis and paragonimiasis.","volume":"14","author":"Keiser","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.3201\/eid2707.203900-202106161102-R20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-3156.2009.02234.x","article-title":"Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya.","volume":"14","author":"Black","year":"2009","journal-title":"Trop Med Int Health"},{"key":"key-10.3201\/eid2707.203900-202106161102-R21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0035-9203(99)90289-4","article-title":"High endemicity of human fascioliasis between Lake Titicaca and La Paz valley, Bolivia.","volume":"93","author":"Esteban","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.3201\/eid2707.203900-202106161102-R22","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1128\/AAC.00828-10","article-title":"In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78.","volume":"54","author":"Duthaler","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2707.203900-202106161102-R23","doi-asserted-by":"publisher","first-page":"e0007779","DOI":"10.1371\/journal.pntd.0007779","article-title":"Evaluation of nitazoxanide treatment following triclabendazole failure in an outbreak of human fascioliasis in Upper Egypt.","volume":"13","author":"Ramadan","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R24","doi-asserted-by":"publisher","first-page":"e71520","DOI":"10.1371\/journal.pone.0071520","article-title":"An outbreak of human fascioliasis gigantica in Southwest China.","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2707.203900-202106161102-R25","unstructured":"Instituto Nacional de Estadistica e Informatica. Provincial and district poverty map, 2013. Lima, Peru [in Spanish] [cited 2020 May 28]. https:\/\/www.inei.gob.pe\/media\/MenuRecursivo\/publicaciones_digitales\/Est\/Lib1261\/Libro.pdf"},{"key":"key-10.3201\/eid2707.203900-202106161102-R26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/vr.c5332","article-title":"Diagnosis and economic consequences of triclabendazole resistance in Fasciola hepatica in a sheep flock in south-east Scotland.","volume":"168","author":"Sargison","year":"2011","journal-title":"Vet Rec"},{"key":"key-10.3201\/eid2707.203900-202106161102-R27","doi-asserted-by":"publisher","first-page":"20130434","DOI":"10.1098\/rstb.2013.0434","article-title":"The contribution of mass drug administration to global health: past, present and future.","volume":"369","author":"Webster","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key-10.3201\/eid2707.203900-202106161102-R28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12879-015-1326-9","article-title":"Diagnosis of human fascioliasis in Arusha region, northern Tanzania by microscopy and clinical manifestations in patients.","volume":"15","author":"Lukambagire","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid2707.203900-202106161102-R29","doi-asserted-by":"publisher","first-page":"e2553","DOI":"10.1371\/journal.pntd.0002553","article-title":"Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide.","volume":"7","author":"Zumaquero-R\u00edos","year":"2013","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/7\/20-3900_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:52:30Z","timestamp":1732989150000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/7\/20-3900_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2707.203900","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}